Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

The unprecedented public health and economic impact of the COVID-19 pandemic caused
by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been …

The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …

Abstract SARS-CoV-2 501Y. V2 (B. 1.351), a novel lineage of coronavirus causing COVID-
19, contains substitutions in two immunodominant domains of the spike protein. Here, we …

The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection has resulted in an unprecedented setback …

As the emerging variants of SARS-CoV-2 continue to drive the worldwide pandemic, there is
a constant demand for vaccines that offer more effective and broad-spectrum protection …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has already infected more
than 500 million people globally (as of May 2022), creating the coronavirus disease 2019 …

Longitudinal analyses of the innate immune system, including the earliest time points, are
essential to understand the immunopathogenesis and clinical course of coronavirus disease …

New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to
arise and prolong the coronavirus disease 2019 (COVID-19) pandemic. Here, we used a …

The Spike protein is the target of both antibody‐based therapeutics (convalescent plasma,
polyclonal serum, monoclonal antibodies) and vaccines. Mutations in Spike could affect …